Merck and Schering-Plough Pharmaceuticals have received approval to include new data in their label for Vytorin (ezetimibe/simvastatin), which the two companies co-market.
The new information states that the drug is more effective than Crestor (rosuvastatin) at lowering LDL cholesterol. A randomized, double-blind, six-week study of 2,959 patients with high LDL cholesterol found that Vytorin provided significantly greater reduction than Crestor when averaged across all dose comparisons and at all individual dose comparisons, ranging from recommended starting doses to the maximum approved doses.
Continue Reading
Vytorin is the first and only product approved to regulate cholesterol by both inhibiting its production in the liver and by blocking its absorption in the intestine, including cholesterol from food.
